当前位置： SCI文献检索 > ANTIVIRAL THERAPY期刊下所有文献 > Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

Abstract：

BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential therapeutics for the treatment of HCV infections. The purpose of this study was to evaluate the safety and pharmacokinetics of an anti-hSR-B1 antibody (Seq2) in cynomolgus monkeys. METHODS:The antibody was administered intravenously at 1, 10 and 100 mg/kg body weight; blood samples were taken pre- and post-dose to evaluate the pharmacokinetic profile and blood chemistry. Safety was assessed during treatment and the animals were sacrificed post-treatment for pathological assessment and liver antibody-receptor occupancy determination. RESULTS:Following administration of Seq2 antibody to cynomolgus monkeys a non-linear pharmacokinetic profile was observed. The clearance of the antibody decreased from 2 to 0.3 ml/h/kg with increasing doses from 1 to 100 mg/kg, respectively, and the antibody half-life varied from 62 to 218 h for the same doses. An increase in total cholesterol and high-density lipoprotein cholesterol levels after antibody administration was observed, with a good correlation between liver receptor occupancy and dose. CONCLUSIONS:The pharmacokinetics and toxicology results were in accordance with the pharmacology of the antibody mechanism. The elevation of total cholesterol was dose-dependent and did not exceed a twofold increase. The safety study indicated no adverse effects during the treatment or in the pathology analysis at any of the doses tested.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Flores MV,Corbau RG,Guionaud S

doi

10.3851/IMP2570

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

775-84

issue

6

eissn

1359-6535

issn

2040-2058

journal_volume

18

pub_type

杂志文章

相关文献

ANTIVIRAL THERAPY文献大全
  • The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1.

    abstract：BACKGROUND:Current stopping rules during pegylated interferon (peg-IFN)/ribavirin (RBV) treatment rely on week 12 HCV RNA response, but earlier identification of non-responders offers clinical and economic advantages. AIMS AND METHODS:To evaluate, among 129 HCV-genotype-1-infected, treatment-naive patients receiving p...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Bárcena R,Moreno A,del Campo S,Muriel A,Mateos ML,Garrido E,García M,Quereda C,Moreno S,Moreno A

    更新日期：2007-01-01 00:00:00

  • Health economics in HIV disease.

    abstract：:All illnesses and, by association, all provision of health care in any setting have a cost, whether it is the direct cost to the consumer, to the provider (for example, a national health service) or the indirect cost to an employer or to society in lost production. Disease also has hidden or intangible costs of pain, ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Youle M

    更新日期：1999-01-01 00:00:00

  • Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

    abstract：:Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP3245

    authors： Forton D,Weissenborn K,Bondin M,Cacoub P

    更新日期：2018-01-01 00:00:00

  • Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

    abstract：BACKGROUND:Sexually transmitted acute hepatitis C among HIV-positive homosexual men has been noted as an emerging epidemic. METHODS:Forty-seven patients with mainly sexually acquired, acute hepatitis C were enrolled in this prospective, multicentre trial, and 36 of these patients were treated within the acute phase of...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Vogel M,Nattermann J,Baumgarten A,Klausen G,Bieniek B,Schewe K,Jessen H,Boesecke C,Rausch M,Lutz T,Fenske S,Schranzo D,Kümmerle T,Schuler C,Theisen A,Mayr C,Seidel T,Rockstroh JK

    更新日期：2006-01-01 00:00:00

  • Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

    abstract：:There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these ag...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Wainberg MA,Sawyer JP,Montaner JS,Murphy RL,Kuritzkes DR,Raffi F

    更新日期：2005-01-01 00:00:00

  • Antiviral activity of FNC, 2'-deoxy-2'-β-fluoro-4'-azidocytidine, against human and duck HBV replication.

    abstract：BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2094

    authors： Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

    更新日期：2012-01-01 00:00:00

  • Smoking motivations and quitting motivations among HIV-infected smokers.

    abstract：BACKGROUND:The aim of this study was to examine smoking motivation and motivation to quit, and determinants of these motivations among HIV-infected cigarette smokers. METHODS:We conducted a 1-day cross-sectional survey on cigarette smoking in a representative sample of HIV-infected outpatients of French hospitals. A c...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1292

    authors： Peretti-Watel P,Garelik D,Baron G,Spire B,Ravaud P,Duval X,EVIT Study Group.

    更新日期：2009-01-01 00:00:00

  • The role of stavudine in the management of adults with HIV infection.

    abstract：:Combinations of two nucleoside analogue reverse transcriptase inhibitors plus a third agent represent the current standard for antiretroviral therapy. Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic in...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Moyle GJ,Gazzard BG

    更新日期：1997-12-01 00:00:00

  • Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy.

    abstract：BACKGROUND:Anaemia has been linked with mortality in HIV infection. The mechanism of anaemia in the era of contemporary antiretroviral therapy is not understood. The aim of this study was to describe the association between anaemia and markers of immune activation and inflammation in a cohort of HIV-infected adults on ...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.3851/IMP2940

    authors： Lipshultz HM,Hileman CO,Ahuja S,Funderburg NT,McComsey GA

    更新日期：2015-01-01 00:00:00

  • Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

    abstract：BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1558

    authors： Jaworsky D,Thompson C,Yudin MH,Bitnun A,Brophy J,Samson L,Antoniou T,Loutfy MR

    更新日期：2010-01-01 00:00:00

  • Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

    abstract：BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2671

    authors： Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

    更新日期：2013-01-01 00:00:00

  • Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.

    abstract：:A novel severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. We previously isolated and characterized SARS-CoV and SARS-CoV-like viruses from human and animals, respectively, suggesting that SARS could be transmitted from wild/farmed animals ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Zheng BJ,Guan Y,Hez ML,Sun H,Du L,Zheng Y,Wong KL,Chen H,Chen Y,Lu L,Tanner JA,Watt RM,Niccolai N,Bernini A,Spiga O,Woo PC,Kung HF,Yuen KY,Huang JD

    更新日期：2005-01-01 00:00:00

  • Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

    abstract：:Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3362

    authors： Xie X,Jiang Y,Zeng Y,Liu H

    更新日期：2020-06-04 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract：:Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：10.3851/IMP2612

    authors： Archambault J,Melendy T

    更新日期：2013-01-01 00:00:00

  • Sodium tanshinone IIA sulfonate inhibits porcine reproductive and respiratory syndrome virus via suppressing N gene expression and blocking virus-induced apoptosis.

    abstract：BACKGROUND:Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant economic loss in the swine industry. Currently, there is no effective way to prevent PRRSV infection. Sodium tanshinone IIA sulfonate (STS), a natural compound derived from Salvia miltiorrhiza, was shown to possess anti-PRRSV acti...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2694

    authors： Sun N,Li E,Wang Z,Zhao J,Wang S,He J,Bai Y,Li H

    更新日期：2014-01-01 00:00:00

  • Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.

    abstract：BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3147

    authors： Bissio E,Barbás MG,Kademián S,Bouzas MB,Salomón H,Cudolá A,Giuliano SF,Falistocco C

    更新日期：2017-01-01 00:00:00

  • The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

    abstract：BACKGROUND:We examined the prevalence of ritonavir-boosted darunavir (DRV) resistance-associated mutations (RAMs) in HIV-infected children in the UK to determine the drug's potential clinical utility as a first-line or second-line protease inhibitor (PI). METHODS:The prevalence of DRV RAMs, identified from IAS 2010 an...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2015

    authors： Donegan KL,Walker AS,Dunn D,Judd A,Pillay D,Menson E,Lyall H,Tudor-Williams G,Gibb DM,Collaborative HIV Paediatric Study.,UK HIV Drug Resistance Database.

    更新日期：2012-01-01 00:00:00

  • Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

    abstract：BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：

    authors： Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

    更新日期：2008-01-01 00:00:00

  • Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.

    abstract：:A 14 year old common variable immunodeficiency patient developed severe protein-losing enteropathy. A chronic enteral infection with human parechovirus type 1 and norovirus was diagnosed. Treatment strategies aimed at virus eradication and providing supportive care were ineffective. The antipicornavirus agent pleconar...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1792

    authors： van de Ven AA,Douma JW,Rademaker C,van Loon AM,Wensing AM,Boelens JJ,Sanders EA,van Montfrans JM

    更新日期：2011-01-01 00:00:00

  • Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.

    abstract：BACKGROUND:This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment. METHODS:A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assesse...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP1664

    authors： Cournil A,Coudray M,Kouanfack C,Essomba CN,Tonfack CA,Biwolé-Sida M,Delaporte E,Bork K,Laurent C

    更新日期：2010-01-01 00:00:00

  • The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

    abstract：BACKGROUND:Nucleoside (or nucleotide) reverse transcriptase inhibitors (NRTIs) cause side effects in some patients, prompting the use of either partly or fully NRTI-sparing regimens. METHODS:We used data from the Swiss HIV Cohort Study to estimate the effectiveness of two new dolutegravir dual regimens relative to the...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3310

    authors： Young J,Scherrer AU,Calmy A,Tarr PE,Bernasconi E,Cavassini M,Hachfeld A,Vernazza P,Günthard HF,Bucher HC,Swiss HIV Cohort Study.

    更新日期：2019-01-01 00:00:00

  • Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.

    abstract：BACKGROUND:In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP2743

    authors： Degasperi E,Valenti L,Aghemo A,De Francesco R,Rumi M,Soffredini R,Donnici L,Cheroni C,Fargion S,Zanoni V,Orsi E,Colombo M

    更新日期：2014-01-01 00:00:00

  • HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

    abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：

    authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

    更新日期：2007-01-01 00:00:00

  • Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.

    abstract：BACKGROUND:Ageing HIV-infected patients present an increased incidence of cardiovascular diseases, endothelial dysfunction being an early alteration. Some protease inhibitors (PIs) have been shown to increase the risk of cardiovascular disease. We evaluated here the effects of CCR5 or integrase inhibitors as compared t...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3160

    authors： Afonso P,Auclair M,Caron-Debarle M,Capeau J

    更新日期：2017-01-01 00:00:00

  • Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.

    abstract：BACKGROUND:IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV-HCV-coinf...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,多中心研究

    doi：10.3851/IMP2921

    authors： Neukam K,Munteanu D,Haubitz S,Mira JA,Ingiliz P,Rivero-Juárez A,Lutz T,de los Santos-Gil I,Scholten S,Márquez M,Rauch A,Rockstroh JK,Pineda JA

    更新日期：2015-01-01 00:00:00

  • Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART.

    abstract：BACKGROUND:This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. METHODS:We included patients in follow-up >5 years after ART initiation. Factors associated with mortality beyond 5 and 10 years on ...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3358

    authors： Bijker R,Kiertiburanakul S,Kumarasamy N,Pujari S,Sun LP,Ng OT,Lee MP,Choi JY,Nguyen KV,Chan YJ,Merati TP,Cuong DD,Ross J,Jiamsakul A,IeDEA Asia-Pacific.

    更新日期：2020-01-01 00:00:00

  • A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.

    abstract：BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,随机对照试验

    doi：

    authors： Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JM

    更新日期：2007-01-01 00:00:00

  • Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.

    abstract：BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

    journal_title：Antiviral therapy

    pub_type： 杂志文章

    doi：10.3851/IMP3137

    authors： Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

    更新日期：2017-01-01 00:00:00

  • Respiratory viral infections in transplant recipients.

    abstract：:A wide range of viruses affect the respiratory tract of transplant recipients, including adenovirus, influenza, human metapneumovirus, parainfluenza virus, respiratory syncytial virus (RSV) and rhinovirus. Prospective studies using contemporary diagnostic techniques have recently improved our understanding of the epid...

    journal_title：Antiviral therapy

    pub_type： 杂志文章,评审

    doi：

    authors： Ison MG

    更新日期：2007-01-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract：BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title：Antiviral therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.3851/IMP3202

    authors： Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期：2018-01-01 00:00:00